Our vision is to transform pulmonary hypertension (PH) into a long-term, manageable condition, so that patients can live a normal life.
At Janssen, we are spearheading a new era for pulmonary hypertension (PH), working to transform the disease into a long-term manageable condition, so that patients can live a normal life.
Building on Actelion's 20-year heritage of pioneering innovation, we are working to ensure that we reach more patients and support them to receive optimal treatment. We continue to take steps towards tackling the diagnosis gap and we are working to find new treatments.
Recognizing Actelion's legacy
In June 2017, Actelion became part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Now, as Janssen PH, one of Janssen’s six therapeutic areas, we are committed to maintaining and building on the leadership position that Actelion has built in pulmonary hypertension.
We respect and value Actelion’s legacy in pulmonary arterial hypertension (PAH), a rare form of PH, and we are proud that the world’s most widely prescribed PH medicines are now part of Janssen’s portfolio.
Building a future Janssen legacy
Like Actelion, Janssen shares the same passion for science and the same dedicated commitment to improving the welfare of patients.
We bring to the field of PH a remarkable track record in scientific discovery and a deep patient-centric focus, underpinned by an open, transparent business culture. 16 of Janssen’s medicines for various diseases are included in the World Health Organization (WHO) Essential Medicines List.